Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and pharmacokinetics of the investigational drug. In cases where the Phase 1 outcome is positive, Galapagos has initiated Phase 2 studies which are conducted in patients, to preliminary measure efficacy suggesting effectiveness and also determine common short-term side effects and risks. These studies are performed by medical doctors who are specialists in the disease area. Galapagos is not allowed to be in any way involved in volunteer/patient enrollment for the conducted clinical trials: whether or not an individual can be included in a clinical study is decided only by the responsible medical doctors after having checked numerous eligibility criteria. In each case, Galapagos cannot and will not influence the specialists' decisions for such inclusion. The patient should contact his/her treating physician, who can then investigate with the clinical study centers the possibility for the patient to be included in a clinical study.
Information about ongoing clinical trials for Galapagos’ investigational drugs is available at clinicaltrials.gov, a service of the U.S. National Institutes of Health that provides details on clinical trials conducted worldwide.
For more information about ongoing clinical trials for:
Next to the information on clinicaltrials.gov, there are several patient information portals where more information regarding Galapagos related Phase 3 studies is to be found. Our partner Gilead launched study information portals regarding Phase 3 studies with filgotinib in Crohn's disease and ulcerative colitis (UC). As sponsor of the Phase 3 study with GLPG1690 in IPF, Galapagos has launched the ISABELA information portal.